A Phase II Study Of Sunitinib In Patients With Progressive Advanced/Metastatic Well-Differentiated Pancreatic Neuroendocrine Tumors.
Phase of Trial: Phase II
Latest Information Update: 02 Sep 2014
At a glance
- Drugs Sunitinib (Primary)
- Indications Neuroendocrine tumours; Pancreatic cancer
- Focus Therapeutic Use
- Sponsors Pfizer
- 07 Jan 2014 According to ClinicalTrials.gov record study status changed from active, no longer recruiting to completed.
- 27 Feb 2013 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.
- 01 Jan 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.